Biocon

Biocon

@Bioconlimited

Followers13.5K
Following320

Delivering Affordable Innovation

Bangalore, India
Joined on October 25, 2011
Statistics

We looked inside some of the tweets by @Bioconlimited and here's what we found interesting.

Inside 100 Tweets

Time between tweets:
2 hours
Average replies
1
Average retweets
8
Average likes
25
Tweets with photos
32 / 100
Tweets with videos
11 / 100
Tweets with links
0 / 100

Rankings (sorted by number of followers)

58. in country India and category Services

510. in country India and category Brands

Breakthrough Drug #Itolizumab receives DCGI Nod for its use in moderate to severe covid-19 patients,the first novel biologic therapy to be approved by DCGI for treating patients with moderate to severe COVID-19 complications
Congratulation @kiranshaw on this achievement. https://t.co/1ZHlOQHann

Breakthrough Drug #Itolizumab receives DCGI Nod for its use in moderate to severe covid-19 patients,the first novel biologic therapy to be approved by DCGI for treating patients with moderate to severe COVID-19 complications Congratulation @kiranshaw on this achievement. https://t.co/1ZHlOQHann

Register today for TiE Austin's upcoming webinar "Compassionate Capitalism", featuring renowned entrepreneur Kiran Mazumdar-Shaw, moderated by Kerry Rupp. Sign up here: https://t.co/vI2yvoBlWM

#TiEAustin #WomenInBusiness #KiranMazumdar #KerryRupp #Biocon #TrueWealthVentures https://t.co/cIAmLMiX77

Register today for TiE Austin's upcoming webinar "Compassionate Capitalism", featuring renowned entrepreneur Kiran Mazumdar-Shaw, moderated by Kerry Rupp. Sign up here: https://t.co/vI2yvoBlWM #TiEAustin #WomenInBusiness #KiranMazumdar #KerryRupp #Biocon #TrueWealthVentures https://t.co/cIAmLMiX77

@kiranshaw It’s definitely a breakthrough and life saving drug when there’s rising cases of Covid and health infrastructure is prohibitively expensive. This biologics is expected to reduce hospital expenses in ICU and Ventilator. Congratulation to team Biocon.

Quoted @rnivruti

Proud of @BioconBiologics from driving #Covid_19 cure with #Itolizumab ! Great job @kiranshaw https://t.co/Ufe4Z17tf7

Totally accede @rnivruti .. Always been a secret admirer of @Bioconlimited and @kiranshaw. Extremely inspiring. Massive respect 🙏 https://t.co/NB8UZLpFNh

Yes, Emergency Use nod is against a Pivotal patient study to address immediate patient needs. More data to be generated through ph 4 study, part of the plan. @Bioconlimited    The Hindu 15 july https://t.co/9hSl1R1CLz

Yes, Emergency Use nod is against a Pivotal patient study to address immediate patient needs. More data to be generated through ph 4 study, part of the plan. @Bioconlimited The Hindu 15 july https://t.co/9hSl1R1CLz

#Itolizumab is a truly  innovative, made in India drug, reports Deccan Chronicle  @Bioconlimited Date - 2020-07-15, Publication - Deccan Chronicle,  Edition - Hyderabad, Source - Nayear Ali, Page - 1, 2 https://t.co/VOR0D6ewEc
2

#Itolizumab is a truly innovative, made in India drug, reports Deccan Chronicle @Bioconlimited Date - 2020-07-15, Publication - Deccan Chronicle, Edition - Hyderabad, Source - Nayear Ali, Page - 1, 2 https://t.co/VOR0D6ewEc

"The advantage of #Itolizumab is that it leads to the downregulation of important cellular pathways that control inflammation. With that, Itolizumab to me is superior to all the agents available.", Dr. Om Shrivastav, Infectious Diseases Specialist. More: https://t.co/EySN7DI8GH https://t.co/nMKB8GD8JU

“Itolizumab is a great drug, which will form a pillar for the prevention and attenuation of the ‘cytokine storm’ observed in COVID-19 patients,” Dr. Hemant Thacker, Sr Physician, Breach Candy Hospital at #Biocon's press conference. https://t.co/EySN7Dqxi7 #UnitedAgainstCOVID19 https://t.co/7C5kaw9SzR

Quoted @adarpoonawalla

Congratulations @kiranshaw and @Bioconlimited, hope this helps in our fight against COVID-19. https://t.co/8JdJeRWiaz

Thank you @adarpoonawalla. #UnitedAgainstCOVID19 https://t.co/uZ9saw9GLz

Many experts have said Biocon’s Itolizumab, which is approved for treating patients with moderate to severe COVID-19 complications in India, is promising. There also seems to be a scientific consensus in favour of a larger trial to be sure of effect. https://t.co/aINb60AI8T

"Moderate, moderate-severe, and severe #COVID19 patients form less than 4-5% of the patient population. #Itolizumab is not a cure to COVID-19, but it is a way to reduce mortality rates," says Dr Hemant Thacker, Breach Candy Hospital, Mumbai. @govindethiraj https://t.co/i7lXFN9OzN

Quoted @CNNnews18

#Alert- Biocon's Covid-19 drug Itolizumab approved for emergency use after trial on only 30 patients. @kiranshaw (Executive Chairperson of Biocon Ltd) speaks to CNN-News18's @snehamordani says 'the drug is not expensive'. Listen in: https://t.co/h8n89RtdvB

“Itolizumab was approved for psoriasis in 2013 after Phase 1, 2 & 3 trials. This is a label extension & because it’s a medical emergency we were able to do a pivotal trial and received approval for restricted emergency use for particular COVID-19 patients.” @kiranshaw https://t.co/XD91E1luxV

"Itolizumab can save lives & mitigate patients from going to a ventilator. Though it's a small clinical trial, we have seen a 30% reduction in the mortality rate.” Dr. Shashank Joshi, Dean-Indian College of Physicians. 
Listen to more insights👉 https://t.co/CGtHvXV0F5 https://t.co/DM7QPlFbuL

"Itolizumab can save lives & mitigate patients from going to a ventilator. Though it's a small clinical trial, we have seen a 30% reduction in the mortality rate.” Dr. Shashank Joshi, Dean-Indian College of Physicians. Listen to more insights👉 https://t.co/CGtHvXV0F5 https://t.co/DM7QPlFbuL

Quoted @boomlive_in

#BOOMExplains: Is @Bioconlimited's psoriasis drug #Itolizumab safe for treatment of moderate to severe cases of #COVID19? Dr Hemant Thacker, Consultant & Senior Physician, Breach Candy Hospital, Mumbai tells @govindethiraj how it works. #CoronaVirusFacts https://t.co/a0T4CiVHVI

“This is a game changer in reducing mortality rate. I have had no adverse reaction in the form of organ threatening or life threatening issues.” Dr Hemant Thacker speaks to @govindethiraj on the safety of Biocon’s Itolizumab approved by DCGI for emergency COVID-19 use. https://t.co/gtXMH3taKU

Quoted @rnivruti

Foc News USA says: “India is way ahead of the curve” Words of such respect, fills my heart with pride, joy and relief! Thanks @Bioconlimited and @kiranshaw for leading India with #innovation for the world to beat the pandemic! https://t.co/OzS2yE6m8S

The #COVID19 emergency has spurred a re-discovery of India's capabilities in high-end scientific research. As an #innovation-led #biopharmaceuticals company from #India, Biocon has risen to the challenge. https://t.co/yg15D4RiIJ

Quoted @rnivruti

Foc News USA says: “India is way ahead of the curve” Words of such respect, fills my heart with pride, joy and relief! Thanks @Bioconlimited and @kiranshaw for leading India with #innovation for the world to beat the pandemic! https://t.co/OzS2yE6m8S

#FoxNews #USA Finds #Itolizumab Data Promising for #COVID19 New Hope for Patients during this pandemic from #India. Quite motivating to see appreciation come in from different quarters @Bioconlimited https://t.co/WWosvQQsYb

Good news @Bioconlimited partner in US @EquilliumBio planning a global controlled clinical trial of 'first in class' #itolizumab drug in COVID-19 patients. Investigational New Drug Application with US FDA to be filed soon. https://t.co/C5X9XdyKzI

.@Bioconlimited's @kiranshaw says after early results started coming out, doctors started using Itolizumab 'off-label'… Encouraging feedback from doctors about good efficacy of Itolizumab.

Will not see any black marketing of #Itolizumab, we will not let it happen, she adds. https://t.co/VVr3gSq7JK

.@Bioconlimited's @kiranshaw says after early results started coming out, doctors started using Itolizumab 'off-label'… Encouraging feedback from doctors about good efficacy of Itolizumab. Will not see any black marketing of #Itolizumab, we will not let it happen, she adds. https://t.co/VVr3gSq7JK

Biocon's Itolizumab becomes the 5th & 1st indigenous drug to receive #DCGI's emergency use approval for #COVID19 treatment. @ShereenBhan talks to @kiranshaw, @DrSidMukherjee, Dr Shashank Joshi & Dr Mohan Joshi about the treatment protocols https://t.co/UAmW4RWfOb

Next Page